PIK3CA and idiopathic pulmonary fibrosis: In preclinical models,omipalisib was shown to reduce fibroblast proliferation and collagensynthesis. A phase I clinical trial (NCT01725139)indicated that omipalisib was safe and demonstrated dose-dependentinhibition of the PI3K/mTOR pathway in individuals with IPF.